| Entry |
|
|---|
| Name |
Zipalertinib (JAN/USAN/INN) |
|---|
| Formula |
C23H20N6O
|
|---|
| Exact mass |
396.1699
|
|---|
| Mol weight |
396.44
|
|---|
| Structure |
|
|---|
| Class |
Antineoplastic
DG01918 Tyrosine kinase inhibitor
DG01917 Receptor tyrosine kinase inhibitor
DG03162 EGFR inhibitor
|
|---|
| Efficacy |
Antineoplastic, Receptor tyrosine kinase inhibitor |
|---|
| Target |
|
|---|
| Pathway |
| hsa01521 | EGFR tyrosine kinase inhibitor resistance |
|
|---|
| Interaction |
|
|---|
| Brite |
Drug groups [BR:br08330]
Antineoplastic
DG01918 Tyrosine kinase inhibitor
DG01917 Receptor tyrosine kinase inhibitor
DG03162 EGFR inhibitor
D13062 Zipalertinib
Target-based classification of drugs [BR:br08310]
Protein kinases
Receptor tyrosine kinases (RTK)
EGFR family
EGFR* [HSA_VAR:1956v2]
D13062 Zipalertinib (JAN/USAN/INN)
|
|---|
| Other DBs |
|
|---|
| LinkDB |
|
|---|
| KCF data |
ATOM 30
1 C8x C 21.6300 -20.6500
2 N5x N 21.6300 -22.0500
3 C8y C 22.8424 -22.7500
4 C8y C 24.0549 -22.0500
5 C8y C 24.0549 -20.6500
6 N5x N 22.8424 -19.9500
7 C8y C 25.3864 -22.4826
8 C8y C 26.2093 -21.3500
9 N4y N 25.3864 -20.2174
10 N1a N 22.8424 -24.1498
11 C8y C 25.8175 -23.8094
12 C2y C 27.6016 -21.2037
13 C2x C 28.1710 -19.9247
14 C1y C 27.3481 -18.7921
15 C1x C 25.9558 -18.9384
16 C1a C 28.4199 -22.3301
17 N1b N 27.9329 -17.4781
18 C5a C 29.3199 -17.3322
19 O5a O 30.1597 -18.4876
20 C2b C 29.8807 -16.0729
21 C2a C 31.2791 -15.9259
22 C8x C 24.8911 -24.8385
23 C8y C 25.3238 -26.1699
24 C8y C 26.6933 -26.4609
25 N5x N 27.6197 -25.4318
26 C8x C 27.1870 -24.1003
27 C8x C 24.3871 -27.2104
28 C8x C 24.8199 -28.5419
29 C8x C 26.1893 -28.8328
30 C8x C 27.1260 -27.7923
BOND 34
1 1 2 2
2 2 3 1
3 3 4 2
4 4 5 1
5 5 6 2
6 1 6 1
7 4 7 1
8 7 8 2
9 8 9 1
10 5 9 1
11 3 10 1
12 7 11 1
13 8 12 1
14 12 13 2
15 13 14 1
16 14 15 1
17 9 15 1
18 12 16 1
19 14 17 1 #Up
20 17 18 1
21 18 19 2
22 18 20 1
23 20 21 2
24 11 22 2
25 22 23 1
26 23 24 2
27 24 25 1
28 25 26 2
29 11 26 1
30 23 27 1
31 27 28 2
32 28 29 1
33 29 30 2
34 24 30 1
|
|---|
